The Associated Press/The Washington Post reports that the AMA on Monday rebuffed dissident members and voted to stick to support for ongoing wellness reform initiatives, while reiterating wariness over proposals that threaten doctors’ pocketbooks and independence. The action at the group’s semiannual interacting with in Houston could possibly be seen as a vote of self-confidence for AMA leaders who voiced support for the $1.2-trillion, 10-year bill the U online-apotek .S.
THE BUSINESS reported a net loss of $18.4 million, or a lack of $1.07 per basic and diluted share, for the one fourth ended December 31, 2009, as in comparison to a net lack of $21.8 million, or a loss of $1.28 per basic and diluted share, for the same period in 2008. Net reduction for the entire year ended December 31, 2009 was $93.4 million, or a loss of $5.46 per basic and diluted share, in comparison with a net lack of $71.6 million, or a loss of $4.22 per diluted and basic share for the same period in 2008. Resource AMAG Pharmaceuticals, Inc.. AMAG Pharmaceuticals reviews fourth-quarter 2009 net product revenues of $12.8M attributable to Feraheme AMAG Pharmaceuticals, Inc. , a biopharmaceutical company centered on the commercialization and development of a therapeutic iron compound to treat iron deficiency anemia and novel imaging brokers to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the fourth one fourth and year ended December 31, 2009.8 million, including $1.3 million of the $11.5 million in deferred item revenues previously.